Share price · TECX
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when TECX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 31 Aug 2026-15.9%
Nothing announced by TECX that day or the session before.
- 18 Aug 2026+8.2%
Nothing announced by TECX that day or the session before.
- 12 Aug 2026+15.6%
Nothing announced by TECX that day or the session before.
- 15 Jul 2026-6.6%
Nothing announced by TECX that day or the session before.
- 6 Jul 2026-7.1%
Nothing announced by TECX that day or the session before.
- 2 Jul 2026+15.9%
Nothing announced by TECX that day or the session before.
- 6 Mar 2026+28.8%
Nothing announced by TECX that day or the session before.
- 4 Mar 2026+12.4%
Nothing announced by TECX that day or the session before.
- 3 Mar 2026+6.1%
- 25 Feb 2026+8.2%
Share of unusual movement by asset
For each asset, the share of TECX's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
Fc-relaxin fusion protein (TX45)events and moves
| 1 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 0% |
| Other company news (earnings, financing, releases naming no asset) | — | 53% |
| Sessions with no dated event | — | 47% |
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | Relaxin receptor (RXFP1) / relaxinProtein / enzyme therapeutic | Pulmonary Hypertension Associated with Interstitial Lung DiseasePulmonary Hypertension due to Left Heart Disease |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
November 2026 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | — | $17M | $235M | $21M-$15M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $18M | $228M | $22M-$21M operating cash flow | report ↗ |
| 2026-Q1 | — | $21M | $237M | $25M-$18M operating cash flow | report ↗ |
| 2025-Q3 | — | $17M | $270M | $19M-$18M operating cash flow | report ↗ |
| 2025-Q2 | — | $17M | $288M | $20M-$15M operating cash flow | report ↗ |
| 2025-Q1 | — | $13M | $307M | $16M-$13M operating cash flow | report ↗ |
| 2024-Q3 | — | $14M | $160M | $18M-$20M operating cash flow | report ↗ |
| 2024-Q2 | — | $7.1M | $186M | $13M-$15M operating cash flow | report ↗ |
| 2024-Q1 | — | $0.7M | $91M | $6.8M-$7.6M operating cash flow | report ↗ |
| 2023-Q3 | — | $15M | $107M | $22M-$20M operating cash flow | report ↗ |
| 2023-Q2 | — | $11M | $125M | —-$15M operating cash flow | report ↗ |
| 2023-Q1 | — | $17M | $73M | $25M-$20M operating cash flow | report ↗ |
| 2022-Q3 | — | $16M | $116M | $23M-$16M operating cash flow | report ↗ |
| 2022-Q2 | — | $19M | $133M | $28M-$29M operating cash flow | report ↗ |
| 2022-Q1 | — | $19M | $162M | $30M-$28M operating cash flow | report ↗ |
| 2021-Q3 | — | $23M | $202M | $33M-$25M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | $63M | $255M | $19M-$60M operating cash flow | report ↗ |
For full-year 2025, Tectonic Therapeutic did not disclose revenue. Research and development expenses were $63.49M, up 53.5% YoY, and cash and cash equivalents were $254.87M. The company reported a net loss of $74.15M for the year.
The company stated its cash position is expected to provide runway into Q4 2028. Clinical developments include positive topline results from the TX45 Phase 1b trial in Group 2 PH-HFrEF announced in October 2025, the first subject randomized in the TX2100 Phase 1a trial in HHT in February 2026, and the activation of the TX45 Phase 2 trial in PH-ILD in February 2026. Tectonic also expects topline results from the TX2100 Phase 1a trial in Q4 2026 and from the TX45 APEX Phase 2 trial in 2026, and announced the appointment of François Nader, M.D., MBA, as an independent director and incoming Board Chair, effective April 1, 2026.
Insider transactions
Open-market activity, trailing 12 months: 3 purchases ($235K), 11 sales ($651K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-10-26 | REICIN ALISE · director, Chief Executive Officer | Option exercise | 10,000 | $2.38 | $24K | Form 4 |
| 2026-10-26 | REICIN ALISE · director, Chief Executive Officer | Option exercise (derivative) | 10,000 | — | — | Form 4 |
| 2026-09-30 | McNamara Peter · Chief Scientific Officer | Open-market sale | 536 | $23.04 | $12K | Form 4 |
| 2026-09-25 | Lochner Daniel · Chief Financial Officer | Tax withholding | 520 | $23.67 | $12K | Form 4 |
| 2026-09-25 | Schwabish Marc · Chief Business Officer | Tax withholding | 411 | $23.67 | $10K | Form 4 |
| 2026-09-25 | REICIN ALISE · director, Chief Executive Officer | Tax withholding | 1,545 | $23.67 | $37K | Form 4 |
| 2026-09-25 | Ruddy Marcella K. · Chief Medical Officer | Tax withholding | 525 | $23.67 | $12K | Form 4 |
| 2026-09-25 | McNamara Peter · Chief Scientific Officer | Tax withholding | 444 | $23.67 | $11K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 111 reporting institutions held 13.8M shares ($411.8M, 69.2% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | FMR LLC | 2,816,494 | $87.1M |
| 2 | TCG Crossover Management, LLC | 1,204,891 | $37.2M |
| 3 | Aberdeen Group plc | 1,141,824 | $35.3M |
| 4 | BlackRock, Inc. | 860,352 | $26.6M |
| 5 | BRAIDWELL LP | 847,151 | $26.2M |
| 6 | First Light Asset Management, LLC | 647,743 | $20.0M |
| 7 | BAKER BROS. ADVISORS LP | 607,788 | $18.8M |
| 8 | 5AM Venture Management, LLC | 606,660 | $18.8M |
| 9 | VANGUARD CAPITAL MANAGEMENT LLC | 473,532 | $14.6M |
| 10 | Vestal Point Capital, LP | 328,000 | $10.1M |
| 11 | KENNEDY CAPITAL MANAGEMENT LLC | 286,682 | $8.9M |
| 12 | GEODE CAPITAL MANAGEMENT, LLC | 268,273 | $8.3M |
| 13 | MARSHALL WACE, LLP | 229,595 | $7.1M |
| 14 | ORBIMED ADVISORS LLC | 226,600 | $7.0M |
| 15 | STATE STREET CORP | 213,505 | $6.6M |